Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 272

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 272
---
 |
| Cash and cash equivalents – end of period                                  |     |      |     |                                 |  3,020 |   |     |      |    216 |   |
| Supplementary information(note 9)                                          |     |      |     |                                 |        |   |     |      |        |   |

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements. F-3 5

Kintara Therapeutics, Inc. Notes to Condensed Consolidated Interim Financial Statements (Unaudited) September 30, 2024 (expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted) 1 Nature of operations, corporate history, and going concern and management plans Nature of operations Kintara Therapeutics, Inc., a Nevada corporation (“Kintara” or, the “Company”) is a clinical-stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing one late-stage therapeutic - REM-001for cutaneous metastatic breast cancer (“CMBC”). In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its current and future product candidates. Merger with TuHURA Biosciences, Inc. On April 2, 2024, the Company entered into a definitive Agreement and Plan of Merger with TuHURA Biosciences, Inc., a Delaware corporation (“TuHURA”), and Kayak Mergeco, Inc., a Delaware corporation wholly owned subsidiary the Company (“Merger Sub”), for an all-stockmerger transaction (the “Merger”) forming a company with expertise and resources to advance a risk diversified late-stage oncology pipeline (the “Merger Agreement”). The Merger Agreement provided that, upon completion of the Merger, the former TuHURA stockholders would own the majority of the shares of the Company. The Merger and other transactions contemplated by the Merger Agreement closed on October 18, 2024 (see note 10). Unless context otherwise requires, the use of “we,” “us,” “our,” and the “Company” in this Report refers to Kintara Therapeutics, Inc., a Nevada corporation pre-Mergerand its wholly owned subsidiaries. Corporate history The Company is a Nevada corporation formed